CDER Compliance Director Recused From Most Duties Due To Husband's Promotion
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
The HHS general counsel determines that to prevent potential conflicts of interest, Cynthia Schnedar must no longer handle substantive issues for compliance actions and policy.
You may also be interested in...
CDER’s New Compliance Director Sklamberg Brings Experience On Compounding Issues
Howard Sklamberg, deputy associate commissioner in FDA’s Office of Regulatory Affairs, will take over as director of the Center for Drug Evaluation and Research’s Compliance Office in January; acting compliance director Ilisa Bernstein will resume her role as deputy director.
US FDA Sets FY 2021 User Fees, With Coronavirus (Somewhat) In Mind
ANDA submission rate increases, while the NDA and BLA fee drops and the biosimilar fee is unchanged.
Pink Sheet Podcast: Coronavirus Vaccines Move Into Phase III, US FDA Coronavirus Workload Changes, Rare Pediatric Priority Review Voucher Expiration
Pink Sheet reporters and editor discuss the start of Phase III coronavirus vaccine trials, FDA’s pandemic work is transitioning away from the idea stage, and the push for a permanent extension of the rare pediatric disease priority review voucher program.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: